Form 4 for TXG 10x Genomics, Inc.
Accepted 2023-12-29 00:00:00 ET · period of report 2023-12-27 · accession 0001610717-23-000426 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-29 | 2023-12-27 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $1.20 | +14.9K | 860.4K | +2% | +$17.9K |
| D | 2023-12-29 | 2023-12-27 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $0.00 | -14.9K | 79.5K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-12-27 | M | A | 14,935 | $1.20 | 860,381 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-12-27 | M | D | 14,935 | $0.00 | 79,463 | D | $1.20 · — to 2027-10-18 | 14,935 Class A Common Stock | (F6) The balance for this grant has been updated from the filing made on December 28, 2021 to reflect the correct amount. (F5) This option, originally for 300,000 shares, of which 220,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021. |